Last reviewed · How we verify

Spinal anesthesia for lumbar surgery: ropivacaine

Fraser Health · Phase 1 active Small molecule Quality 0/100

Spinal anesthesia for lumbar surgery: ropivacaine is a Small molecule drug developed by Fraser Health. It is currently in Phase 1 development. Also known as: Ropivacaine in the spinal anesthesia for lower lumbar surgery.

At a glance

Generic nameSpinal anesthesia for lumbar surgery: ropivacaine
Also known asRopivacaine in the spinal anesthesia for lower lumbar surgery
SponsorFraser Health
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Spinal anesthesia for lumbar surgery: ropivacaine

What is Spinal anesthesia for lumbar surgery: ropivacaine?

Spinal anesthesia for lumbar surgery: ropivacaine is a Small molecule drug developed by Fraser Health.

Who makes Spinal anesthesia for lumbar surgery: ropivacaine?

Spinal anesthesia for lumbar surgery: ropivacaine is developed by Fraser Health (see full Fraser Health pipeline at /company/fraser-health).

Is Spinal anesthesia for lumbar surgery: ropivacaine also known as anything else?

Spinal anesthesia for lumbar surgery: ropivacaine is also known as Ropivacaine in the spinal anesthesia for lower lumbar surgery.

What development phase is Spinal anesthesia for lumbar surgery: ropivacaine in?

Spinal anesthesia for lumbar surgery: ropivacaine is in Phase 1.

Related